汗腺膿瘍の市場規模、シェア、成長分析、皮膚症状別、治療法別、臨床ステージ別、投与経路別、エンドユーザー別、流通チャネル別、地域別 - 産業予測、2025年～2032年

汗腺膿瘍の世界市場規模は2023年に11億4,000万米ドルで、2024年の12億米ドルから2032年には17億5,000万米ドルに成長すると予測され、予測期間（2025-2032年）のCAGRは5.1％です。

汗腺膿瘍の世界市場は、罹患率の上昇、診断の強化、治療方法の改善によって力強い成長を遂げています。患者やヘルスケア提供者の意識の高まりも市場の勢いに寄与しています。研究開発への多額の投資により、炎症管理をターゲットとした生物製剤やドラッグデリバリーシステムの開発が進んでおり、製薬企業はモノクローナル抗体や免疫抑制剤の臨床試験に注力しています。希少疾病用医薬品（オーファンドラッグ）の指定など、支援的な規制の枠組みが技術革新を促進しています。さらに、新興市場におけるヘルスケアインフラの進歩や皮膚科サービスへのアクセスの向上が成長を後押ししています。長時間作用型注射薬や皮下注射薬、高度な診断ツールや低侵襲手術などの技術革新は、治療効果を高め、患者の転帰を改善しています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 技術分析
• ケーススタディ
• 顧客購買行動分析

汗腺膿瘍市場規模：皮膚症状別& CAGR（2025-2032）

• 市場概要
• ニキビ
• 毛包炎
• 嚢胞や黒ずみのような深いニキビ
• 沸騰

汗腺膿瘍市場規模：治療法別& CAGR（2025-2032）

• 市場概要
• 薬
• 手術
• 光線力学療法
• レーザー治療
• その他

汗腺膿瘍市場規模：臨床ステージ別& CAGR（2025-2032）

• 市場概要
• ハーレーステージ1
• ハーレーステージ2
• ハーレーステージ3

汗腺膿瘍市場規模：投与経路別& CAGR（2025-2032）

• 市場概要
• 経口
• 非経口
• その他

汗腺膿瘍市場規模：エンドユーザー別& CAGR（2025-2032）

• 市場概要
• 病院
• 専門クリニック
• ホームケア
• その他

汗腺膿瘍市場規模：流通チャネル別& CAGR（2025-2032）

• 市場概要
• 病院薬局
• 小売薬局
• オンライン薬局
• その他

汗腺膿瘍市場規模& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024年）

主要企業プロファイル

• GlaxoSmithKline（UK）
• Dr. Reddy's Laboratories（India）
• Glenmark（India）
• Boehringer Ingelheim（Germany）
• Pfizer（USA）
• Novartis AG（Switzerland）
• Teva Pharmaceutical（Israel）
• Aurobindo Pharma（India）

結論と提言

Global Hidradenitis Suppurativa Market size was valued at USD 1.14 Billion in 2023 poised to grow to from USD 1.2 Billion in 2024 to USD 1.75 Billion by 2032, growing at a CAGR of 5.1% in the forecast period (2025-2032).

The global market for hidradenitis suppurativa is witnessing robust growth, fueled by rising incidence of the condition, enhanced diagnostics, and improved treatment modalities. Increased awareness among patients and healthcare providers is also contributing to market momentum. Significant investment in research and development has led to advancements in biologics and drug delivery systems targeting inflammation management, with pharmaceutical companies focusing on clinical trials for monoclonal antibodies and immunosuppressants. Supportive regulatory frameworks, including orphan drug designations, are fostering innovation. Furthermore, advancements in healthcare infrastructure in emerging markets and increased access to dermatology services are propelling growth. Technological innovations, such as long-acting and subcutaneous injectables, along with sophisticated diagnostic tools and minimally invasive procedures, are enhancing treatment effectiveness and supporting better patient outcomes.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hidradenitis Suppurativa market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hidradenitis Suppurativa Market Segments Analysis

Global Hidradenitis Suppurativa Market is segmented by Skin Condition, Treatment, Clinical Stage, Route of Administration, End-Users, Distribution Channel and region. Based on Skin Condition, the market is segmented into Pimples, Folliculitis, Deep acne Like Cyst and Blackheads and Boils. Based on Treatment, the market is segmented into Medication, Surgery, Photodynamic Therapy, Laser Treatment and Others. Based on Clinical Stage, the market is segmented into Hurley Stage 1, Hurley Stage 2 and Hurley Stage 3. Based on Route of Administration, the market is segmented into Oral, Parenteral and Others. Based on End-Users, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hidradenitis Suppurativa Market

The global market for hidradenitis suppurativa is being significantly driven by the increasing prevalence of skin diseases, which has led to a heightened demand for effective treatment options. As awareness of chronic skin conditions grows and diagnosis rates rise, there is an urgent need for innovative therapies. This has prompted pharmaceutical companies to invest heavily in research and development, resulting in the expansion of new treatment alternatives. The continuous focus on innovation is enhancing the landscape of hidradenitis suppurativa therapies, making effective management more accessible to those affected by this challenging condition.

Restraints in the Global Hidradenitis Suppurativa Market

The global market for hidradenitis suppurativa faces significant challenges due to the widespread underdiagnosis of the condition by both patients and primary care providers. Often mismanaged as a benign skin infection, hidradenitis suppurativa typically receives inadequate or delayed treatment. This lack of timely diagnosis not only exacerbates the disease progression but also hampers effective management strategies. Consequently, patients are often deprived of access to targeted therapies that could significantly improve their quality of life. This limitation ultimately hinders the overall growth and development of the hidradenitis suppurativa market, creating a pressing need for awareness and education among both healthcare professionals and patients.

Market Trends of the Global Hidradenitis Suppurativa Market

The global hidradenitis suppurativa market is witnessing significant growth driven by advancements in biologic therapies, which offer enhanced efficacy for patients suffering from moderate to severe forms of the disease. Biologics, with their targeted mechanisms of action, are outpacing traditional treatment options and have become key in improving patient outcomes. The landscape is further energized by the continuous initiation of clinical trials and the recent approvals of innovative biologic agents, fostering a dynamic environment for market expansion. This trend signifies a shift towards personalized medicine, dramatically transforming the treatment paradigm for hidradenitis suppurativa and enhancing overall patient care.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Analysis
• Case Studies
• Customer Buying Behavior Analysis

Global Hidradenitis Suppurativa Market Size by Skin Condition & CAGR (2025-2032)

• Market Overview
• Pimples
• Folliculitis
• Deep acne Like Cyst and Blackheads
• Boils

Global Hidradenitis Suppurativa Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Medication
• Surgery
• Photodynamic Therapy
• Laser Treatment
• Others

Global Hidradenitis Suppurativa Market Size by Clinical Stage & CAGR (2025-2032)

• Market Overview
• Hurley Stage 1
• Hurley Stage 2
• Hurley Stage 3

Global Hidradenitis Suppurativa Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Parenteral
• Others

Global Hidradenitis Suppurativa Market Size by End-Users & CAGR (2025-2032)

• Market Overview
• Hospitals
• Specialty Clinics
• Homecare
• Others

Global Hidradenitis Suppurativa Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Hidradenitis Suppurativa Market Size & CAGR (2025-2032)

• North America (Skin Condition, Treatment, Clinical Stage, Route of Administration, End-Users, Distribution Channel)
  • US
  • Canada
• Europe (Skin Condition, Treatment, Clinical Stage, Route of Administration, End-Users, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Skin Condition, Treatment, Clinical Stage, Route of Administration, End-Users, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Skin Condition, Treatment, Clinical Stage, Route of Administration, End-Users, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Skin Condition, Treatment, Clinical Stage, Route of Administration, End-Users, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• GlaxoSmithKline (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Glenmark (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations